Extracellular vesicles and their cells of origin: Open issues in autoimmune diseases.

Haghighitalab, A; Dominici, M; Matin, MM; Shekari, F; Ebrahimi Warkiani, M; Lim, R; Ahmadiankia, N; Mirahmadi, M; Bahrami, AR; Bidkhori, HR

Extracellular vesicles and their cells of origin: Open issues in autoimmune diseases.

Haghighitalab, A Dominici, M Matin, MM Shekari, F Ebrahimi Warkiani, M

Lim, R Ahmadiankia, N Mirahmadi, M Bahrami, AR Bidkhori, HR

Permalink

Publisher:: FRONTIERS MEDIA SA
Publication Type:: Journal Article
Citation:: Front Immunol, 2023, 14, pp. 1090416
Issue Date:: 2023

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Download Published versionAdobe PDF (3.69 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Haghighitalab, A
dc.contributor.author	Dominici, M
dc.contributor.author	Matin, MM
dc.contributor.author	Shekari, F
dc.contributor.author	Ebrahimi Warkiani, M https://orcid.org/0000-0002-4184-1944
dc.contributor.author	Lim, R
dc.contributor.author	Ahmadiankia, N
dc.contributor.author	Mirahmadi, M
dc.contributor.author	Bahrami, AR
dc.contributor.author	Bidkhori, HR
dc.date.accessioned	2023-10-11T03:13:55Z
dc.date.available	2023-02-20
dc.date.available	2023-10-11T03:13:55Z
dc.date.issued	2023
dc.identifier.citation	Front Immunol, 2023, 14, pp. 1090416
dc.identifier.issn	1664-3224
dc.identifier.issn	1664-3224
dc.identifier.uri	http://hdl.handle.net/10453/172627
dc.description.abstract	The conventional therapeutic approaches to treat autoimmune diseases through suppressing the immune system, such as steroidal and non-steroidal anti-inflammatory drugs, are not adequately practical. Moreover, these regimens are associated with considerable complications. Designing tolerogenic therapeutic strategies based on stem cells, immune cells, and their extracellular vesicles (EVs) seems to open a promising path to managing autoimmune diseases' vast burden. Mesenchymal stem/stromal cells (MSCs), dendritic cells, and regulatory T cells (Tregs) are the main cell types applied to restore a tolerogenic immune status; MSCs play a more beneficial role due to their amenable properties and extensive cross-talks with different immune cells. With existing concerns about the employment of cells, new cell-free therapeutic paradigms, such as EV-based therapies, are gaining attention in this field. Additionally, EVs' unique properties have made them to be known as smart immunomodulators and are considered as a potential substitute for cell therapy. This review provides an overview of the advantages and disadvantages of cell-based and EV-based methods for treating autoimmune diseases. The study also presents an outlook on the future of EVs to be implemented in clinics for autoimmune patients.
dc.format	Electronic-eCollection
dc.language	eng
dc.publisher	FRONTIERS MEDIA SA
dc.relation.ispartof	Front Immunol
dc.relation.isbasedon	10.3389/fimmu.2023.1090416
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1107 Immunology, 1108 Medical Microbiology
dc.subject.classification	3101 Biochemistry and cell biology
dc.subject.classification	3105 Genetics
dc.subject.classification	3204 Immunology
dc.subject.mesh	Humans
dc.subject.mesh	Extracellular Vesicles
dc.subject.mesh	Mesenchymal Stem Cells
dc.subject.mesh	Autoimmune Diseases
dc.subject.mesh	Stem Cells
dc.subject.mesh	Stem Cells
dc.subject.mesh	Mesenchymal Stem Cells
dc.subject.mesh	Humans
dc.subject.mesh	Autoimmune Diseases
dc.subject.mesh	Extracellular Vesicles
dc.subject.mesh	Humans
dc.subject.mesh	Extracellular Vesicles
dc.subject.mesh	Mesenchymal Stem Cells
dc.subject.mesh	Autoimmune Diseases
dc.subject.mesh	Stem Cells
dc.title	Extracellular vesicles and their cells of origin: Open issues in autoimmune diseases.
dc.type	Journal Article
utslib.citation.volume	14
utslib.location.activity	Switzerland
utslib.for	1107 Immunology
utslib.for	1108 Medical Microbiology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
pubs.organisational-group	/University of Technology Sydney/Centre for Health Technologies (CHT)
utslib.copyright.status	open_access	*
dc.date.updated	2023-10-11T03:13:48Z
pubs.publication-status	Published online
pubs.volume	14

Abstract:

The conventional therapeutic approaches to treat autoimmune diseases through suppressing the immune system, such as steroidal and non-steroidal anti-inflammatory drugs, are not adequately practical. Moreover, these regimens are associated with considerable complications. Designing tolerogenic therapeutic strategies based on stem cells, immune cells, and their extracellular vesicles (EVs) seems to open a promising path to managing autoimmune diseases' vast burden. Mesenchymal stem/stromal cells (MSCs), dendritic cells, and regulatory T cells (Tregs) are the main cell types applied to restore a tolerogenic immune status; MSCs play a more beneficial role due to their amenable properties and extensive cross-talks with different immune cells. With existing concerns about the employment of cells, new cell-free therapeutic paradigms, such as EV-based therapies, are gaining attention in this field. Additionally, EVs' unique properties have made them to be known as smart immunomodulators and are considered as a potential substitute for cell therapy. This review provides an overview of the advantages and disadvantages of cell-based and EV-based methods for treating autoimmune diseases. The study also presents an outlook on the future of EVs to be implemented in clinics for autoimmune patients.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/172627